

Adrian Krainer is the St. Giles Foundation Professor at Cold Spring Harbor Laboratory, where his group researches the mechanisms and regulation of human pre-mRNA splicing, the role of splicing dysregulation in genetic diseases and cancer, and the development of antisense therapeutics. He is a founder and Director of Stoke Therapeutics. His basic and applied research contributions, particularly to the development of Spinraza for spinal muscular atrophy, have been recognized with the Life Sciences Breakthrough Prize, the Wolf Prize in Medicine, and the RNA Society's Lifetime Achievement Award, as well as membership in the US National Academy of Sciences and the National Academy of Medicine.